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Background {#sec005}
==========

Constantly rising heart failure (HF) prevalence is a major clinical and public health concern. Despite compelling advancements in pharmacological and device-based treatment of HF, the mortality is still high \[[@pone.0225829.ref001], [@pone.0225829.ref002]\]. Coronary artery disease is a major risk factor for the incidence and decompensation of HF, which is the leading cause of hospitalizations, resulting in more than 1 million admissions in both the United States and Europe \[[@pone.0225829.ref003], [@pone.0225829.ref004]\]. From the clinical point of view, it seems crucial to identify the patients with the highest risk of such events and ensure that they receive expanded ambulatory care, which would translate into a reduced number of hospitalizations.

Over the years, many prognostic risk factors for HF exacerbation have been identified, including clinical, laboratory and echocardiographic parameters. Among the clinical parameters, the well-known are: new coronary events, poorly controlled hypertension, both ventricular and supraventricular arrhythmias with rapid ventricular rate, infections---especially respiratory system, high NYHA functional class, short distance in a 6-minute walk test, the presence of comorbidities, in particular: coronary artery disease, diabetes, renal failure, anemia and depression. In the group of laboratory parameters, increased levels of natriuretic peptides, troponins, catecholamine's, urea, creatinine and low sodium levels have high prognostic value. In addition, one should not forget about other sociodemographic factors such as: age, marital status, compliance with dietary and therapeutic recommendations \[[@pone.0225829.ref005]--[@pone.0225829.ref009]\]. Many prior publications emphasize the usefulness ​​of left ventricular (LV) ejection fraction (LVEF) assessment, which was considered one of the most important risk factors for morbidity and mortality. Nevertheless better parameters are still sought. Two-dimensional speckle tracking echocardiography (2D STE) opens new diagnostic possibilities as a valuable tool to assess LV function. LV global longitudinal strain (GLS) has emerged as a parameter which is more sensitive and objective than LVEF in evaluation of LV abnormalities \[[@pone.0225829.ref010], [@pone.0225829.ref011]\]. This was firmly established in various studies as a reliable indicator of prognosis for the broad spectrum of cardiovascular diseases \[[@pone.0225829.ref012]--[@pone.0225829.ref019]\]. However, these studies were primarily focused on other endpoints than HF decompensation. Therefore, **the aim of our study** was to verify whether GLS of the LV derived by 2D STE provides, independently of other well-known clinical parameters, an additional impact on the risk of hospitalization due to HF decompensation in clinically stable outpatients with LV systolic dysfunction of ischemic origin.

Methods {#sec006}
=======

Study design and patient population {#sec007}
-----------------------------------

Between October 2009 and October 2018 we prospectively enrolled consecutive stable patients with ischemic HF and LVEF ≤ 50%. The protocol of the study was approved by the Local Ethics Committee of the Medical University of Gdansk. Several clinical parameters were taken into account: a comprehensive baseline clinical history and physical examination, 12-lead ECG, routine laboratory blood tests and 2D-transthoracic echocardiography parameters, medical treatment and concomitant diseases. All patients had sinus rhythm and were clinically stable for at least 3 months before the enrollment. Patients received optimal medical therapy and coronary revascularization according to current guidelines \[[@pone.0225829.ref020]--[@pone.0225829.ref023]\]. The exclusion criteria were: age \< 18 years, permanent atrial fibrillation/flutter, ventricular paced rhythm, NYHA functional class IV, clinical features of coronary instability at the moment of enrolment, a revascularization (coronary angioplasty or/and surgery by-pass) within 3 months prior to the study, or incomplete coronary revascularization status (scheduled control coronarography, coronary angioplasty or surgery by-pass), and non-cardiologic comorbidities with potential unfavorable effect on survival.

Echocardiography {#sec008}
----------------

Transthoracic echocardiography was performed in patients in the left lateral decubitus position using a GE VIVID E9 ultrasound system (*GE Ultrasound*, *Horten*, *Norway*) equipped with phased-array transducer (M5S). Data were acquired from parasternal long-and short-axis views and the three standard apical views. For each view, cine loops were obtained by recording 3 consecutive heart cycles. Grayscale recordings were optimized for LV evaluation at a frame rate of 50--80 frames per second. All echocardiograms were stored digitally and analyzed with offline software on EchoPAC workstation (*v201*, *GE Healthcare*, *Horten*, *Norway*). Standard echocardiographic parameters such as: LV end-diastolic (EDV) and end-systolic (ESV) volume, left atrium diameter (LADs) were analyzed according to the principles described in the recommendations \[[@pone.0225829.ref024], [@pone.0225829.ref025]\]. LVEF was measured by Simpson's biplane method.

### Analysis of GLS {#sec009}

LV longitudinal function was assessed by the semiautomatic algorithm (*Automated Function Imaging*, *GE*, *Horten*, *Norway*). Briefly, three myocardial markers were placed in an end-diastolic frame in the apical 4-, 2- and 3-chamber views, respectively. The software automatically tracked the contour of the myocardium throughout the heart cycle to cover the entire thickness of the LV wall. Adequate tracking could be verified in real time and corrected by adjusting the region of interest or by manually correcting the contour to ensure optimal tracking. The value of peak GLS derived by 2D STE was analyzed from three apical views and calculated in the 17 segments (6 basal, 6 mid, 4 apical and the apex) in relation to the strain magnitude at aortic valve closure (identified on continuous wave Doppler recording through the aortic valve in 5-chamber view) \[[@pone.0225829.ref026]\]. The authors established that in the present study the higher absolute value of peak GLS (more negative) is assumed to be as better, and the value closer to zero is described as worse.

Follow-up {#sec010}
---------

All patients were followed-up at the University outpatient clinic every 6 months, or earlier if it was clinically required. The primary endpoint was hospitalization due to HF exacerbation (worsening signs of LV or right ventricular failure resulting in administration of intravenous diuretics) including those with fatal outcome (EVENT). The first episode of the EVENT was the end of follow-up period for a given patient. None of the patients were lost during the follow up.

Statistics {#sec011}
----------

Continuous data are presented as the median (25^th^ - 75^th^ percentiles), or numbers (n) and percentages (%). Comparisons between EVENT(+) and EVENT(-) group were made with the Fisher\'s exact test, U Mann-Whitney's test or paired Student\'s t-test. An association between the analyzed parameters and the endpoint was assessed using the Cox hazard models. The accuracy of pre-specified cut-off values for analyzed parameters and their association as potential predictors of the study endpoint was determined by area (AUC) under the receiver-operating characteristic (ROC) curve. The time course of the endpoint, stratified according to the established cut-off value for GLS, was estimated using the Kaplan-Meier method, and the association between compared groups was estimated by the log-rank test. All the results were considered statistically significant at p ≤ 0.05. The statistical analysis was conducted with STATISTICA 9.0 (*StatSoft*, *Tulsa OK*, *USA*) and R 2.15.2.

Results {#sec012}
=======

Clinical characteristics of the studied patients {#sec013}
------------------------------------------------

Finally, 193 patients who met the inclusion criteria were enrolled. The average age of patients was 64 (58--72) years, most of them were men (92%) and 91% underwent myocardial infarction, average LVEF was 33% and GLS -12.3%. Concomitant diseases such as diabetes, hypertension, chronic kidney disease (in stage III or higher) and hypercholesterolemia were present in 53 (27%), 131 (68%), 43 (23%) and 132 (68%), respectively. Regarding pharmacotherapy, a significant proportion of patients received an optimal medical therapy. Baseline clinical, demographic and echocardiographic characteristics of the entire study group are presented in [Table 1](#pone.0225829.t001){ref-type="table"}.

10.1371/journal.pone.0225829.t001

###### Clinical, laboratory and echocardiographic characteristics of the study group and comparison between the EVENT(+) and EVENT(-) groups.

![](pone.0225829.t001){#pone.0225829.t001g}

  -------------------------------------------------------------------------------------------------------------------------------------------------
                                                  All\             EVENT(+)\           EVENT(-)\           [\*](#t001fn002){ref-type="table-fn"}p
                                                  n = 193          n = 58              n = 135             
  ----------------------------------------------- ---------------- ------------------- ------------------- ----------------------------------------
  Age (years)                                     64 (58--72)      67 (59--75)         64 (58--70)         \< 0.044

  Male, n (%)                                     177 (92)         53 (91)             124 (92)            1.000

  Myocardial infarction, n (%)                    175 (91)         51 (88)             124 (92)            0.423

  Revascularization, n (%)                        173 (90)         53 (91)             120 (89)            0.798

  QRS (ms)                                        90 (110--130)    120 (100--160)      110 (90--120)       \< 0.001

  ICD, n (%)                                      115 (60)         50 (86)             65 (48)             \< 0.001

  CRT-D, n (%)                                    17 (9)           10 (17)             7 (5)               \< 0.011

  *NYHA class*                                    \< 0.001                                                 

  NYHA I, n (%)                                   34 (18)          5 (9)               29 (21)             

  NYHA II, n (%)                                  127 (66)         35 (60)             92 (68)             

  NYHA III, n (%)                                 32 (17)          18 (30)             14 (10)             

  *Laboratory parameters*                                                                                  

  Hemoglobin (g/dl)                               14 (13--15)      13.8 (12.6--14.5)   14.1 (13.7--14.8)   \<0.049

  BNP (pg/ml)                                     108 (77--300)    232 (104--1046)     104 (64--200)       \< 0.018

  *Echocardiographic parameters*                                                                           

  LADs (mm)                                       45 (41--48)      46 (43--50)         44 (40--48)         \< 0.005

  EDV (ml)                                        157 (125--200)   170 (136--243)      153 (114--197)      \< 0.029

  ESV (ml)                                        99 (77--134)     120 (96--171)       88 (69--127)        \< 0.001

  LVEF (%)                                        33 (27--40)      28 (23--33)         35 (30--40)         \< 0.001

  GLS (%)                                         -12.3\           -8.4\               -12.6\              \< 0.009
                                                  (-14.9 ---9.7)   (-8.9 ---7.6)       (-14.9 ---10.3)     

  *Medications*                                                                                            

  beta-adrenolytics, n (%)                        184 (95)         52 (90)             132 (98)            \< 0.023

  ACE-inhibitor or ARB, n (%)                     178 (92)         55 (95)             123 (91)            0.559

  spironolactone/eplerenone, n (%)                100 (52)         31 (53)             69 (51)             0.875

  antiplatelet therapy, n (%)                     175 (91)         51 (88)             124 (92)            0.423

  statins, n (%)                                  174 (90)         55 (95)             119 (88)            0.193

  digoxin, n (%)                                  6 (3)            5 (9)               1 (1)               \< 0.010

  diuretics, n (%)                                89 (46)          38 (66)             51 (38)             \< 0.001

  *Concomitant diseases*                                                                                   

  Arterial hypertension, n (%)                    131 (68)         41 (71)             90 (67)             0.618

  Diabetes, n (%)                                 53 (27)          26 (45)             27 (20)             \< 0.001

  GFR \< 60 ml/min/1.73 m^2^, n (%)               43 (22)          25 (43)             18 (13)             \< 0.001

  Hypercholesterolemia, n (%)                     132 (68)         39 (67)             93 (69)             0.867

  History of atrial fibrillation/flutter, n (%)   41 (21)          17 (29)             24 (18)             0.085

  Smoking, n (%)                                  142 (74)         44 (76)             98 (73)             0.723
  -------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ACE--angiotensin converting enzyme, ARB--angiotensin receptor blocker; BNP--brain natriuretic peptide; CRT-D--implantable cardioverter defibrillator with cardiac resynchronization therapy; LADs--left atrium diameter; LVEF--left ventricular ejection fraction; EDV--left ventricular end-diastolic volume; ESV--left ventricular end-systolic volume; GFR--glomerular filtration rate; GLS--global longitudinal strain; ICD--implantable cardioverter defibrillator; MI--myocardial infarction; NYHA--classification according the New York Heart Association; QRS--QRS complex width

\*p value for comparison between EVENT(+) and EVENT(-) groups

During 34 (14--71) month follow-up, 58 patients (30%) reached the study endpoint. Patients from the EVENT(+) group were older, had a wider QRS complex, more advanced NYHA functional class, lower hemoglobin, higher brain natriuretic peptide (BNP) level, they were more likely to have diabetes, chronic kidney disease, they less likely used beta-blockers but more often diuretics and digoxin. With regard to the echocardiographic examination, EVENT(+) patients had larger LADs, greater EDV and ESV as well as lower LVEF and worse GLS: respectively -8.4% (-8.9 ---7.6) versus -12.6% (-14.9 ---10.3) in EVENT(-) group (p \< 0.009). [Fig 1](#pone.0225829.g001){ref-type="fig"} illustrates the example of GLS measurements with severely decreased average GLS value of -7.8% in patient who was hospitalized due to HF decompensation. [Fig 2](#pone.0225829.g002){ref-type="fig"} presents the example of GLS measurements with moderately reduced average GLS value of -14% in patient who didn\'t reach study endpoint within follow-up period.

![The example of global LV longitudinal strain measurements from long-axis, 2- and 4-chumber views, and „Bull's-eye" representation of regional strains in patient who was hospitalized due to HF decompensation.\
Average GLS is -7.8%.](pone.0225829.g001){#pone.0225829.g001}

![The example of global LV longitudinal strain measurements from long-axis, 2- and 4-chumber views, and „Bull's-eye" representation of regional strains in patient who didn't reach the study endpoint within follow-up period.](pone.0225829.g002){#pone.0225829.g002}

Predictors of hospitalization due to HF decompensation {#sec014}
------------------------------------------------------

Univariate Cox analyses revealed age, QRS, NYHA functional class III, hemoglobin, BNP, LADs, EDV, ESV, LVEF, GLS, absence of beta-blockers, use of diuretics, diabetes and GFR \< 60 ml/min/1.73 m^2^ as significant predictors of the EVENT. Pre-specified cut-off values with the highest risk of the EVENT were: age ≥ 72 years, QRS ≥ 118 ms, hemoglobin \< 14.8 g/dl, BNP ≥ 214 pg/ml, LAD ≥ 45 mm, EDV ≥ 166 ml, ESV ≥ 89 ml, LVEF \< 32%, GLS ≥ -9.4% ([Table 2](#pone.0225829.t002){ref-type="table"}).

10.1371/journal.pone.0225829.t002

###### Results of Cox proportional hazard regression analysis for analyzed parameters and their pre-specified cut-off values as predictors of the EVENT during follow-up period.

![](pone.0225829.t002){#pone.0225829.t002g}

  Parameter                    Univariate analysis   [\*](#t002fn002){ref-type="table-fn"}p   
  ---------------------------- --------------------- ---------------------------------------- ----------
  Age (years)                  1.05                  1.01--1.08                               \< 0.005
  Age ≥ 72 (years)             2.48                  1.46--4.23                               \< 0.001
  QRS (ms)                     1.01                  1--1.02                                  \< 0.004
  QRS ≥ 118 (ms)               1.99                  1.14--3.49                               \< 0.016
  NYHA class III               2.35                  1.34--4.13                               \< 0.003
  Hemoglobin (g/dl)            0.82                  0.69--0.98                               \< 0.029
  Hemoglobin \< 14.8 (g/dl)    3.02                  1.19--7.7                                \< 0.002
  BNP (pg/ml)                  1.00                  1--1                                     \< 0.004
  BNP ≥ 214 (pg/ml)            2.64                  1.13--5.31                               \< 0.006
  LAD (mm)                     1.07                  1.02--1.12                               \< 0.004
  LAD ≥ 45 (mm)                2.08                  1.18--3.68                               \< 0.011
  EDV (ml)                     1.01                  1--1.01                                  \< 0.021
  EDV ≥ 166 (ml)               1.83                  0.91--3.69                               \< 0.089
  ESV (ml)                     1.01                  1--1.01                                  \< 0.013
  ESV ≥ 89 (ml)                2.64                  1.01--6.87                               \< 0.047
  LVEF (%)                     0.93                  0.9--0.96                                \< 0.001
  LVEF \< 32 (%)               2.76                  1.55--4.9                                \< 0.001
  GLS (%)                      1.32                  1--1.74                                  \< 0.049
  GLS ≥ -9.4 (%)               15.16                 1.81--126.91                             \< 0.012
  Abscence of betablockers     4.21                  1.76--10.9                               \< 0.001
  Diuretics                    2.17                  1.26--3.73                               \< 0.005
  Diabetes                     2.45                  1.46--4.14                               \< 0.001
  GFR \< 60 ml/min/1.73 m^2^   3.16                  1.87--5.34                               \< 0.001

Abbreviations: BNP--brain natriuretic peptide; CI--confidence interval; LADs--left atrium diameter; LVEF--left ventricular ejection fraction; EDV--left ventricular end-diastolic volume; ESV--left ventricular end-systolic volume; GFR--glomerular filtration rate; GLS--global longitudinal strain; HR--hazard ratio; NYHA--classification according the New York Heart Association; QRS--QRS complex width

\*p value for comparison between EVENT(+) and EVENT(-) groups

ROC analysis identified GLS as the most accurate predictor of hospitalization due to HF decompensation among all the studied continuous variables (AUC 0.81, hazard ratio \[HR\] 15.16, 95% confidence interval \[CI\] 1.81--126.91, p \< 0.012) with high positive predictive value (PPV) of 98%, whereas the rest of the analyzed parameters were characterized by lower discriminatory powers as presented in [Table 3](#pone.0225829.t003){ref-type="table"}.

10.1371/journal.pone.0225829.t003

###### Prognostic accuracy of the pre-specified cut-off values for analyzed parameters as the predictors of the EVENT during the follow-up.

![](pone.0225829.t003){#pone.0225829.t003g}

  Parameters                  AUC        Characteristics (95% CI)   Predictive Value (95% CI)            
  --------------------------- ---------- -------------------------- --------------------------- -------- --------
  Age ≥ 72 (years)            0.59       80                         40                          76       46
  QRS ≥ 118 (ms)              0.67       61                         68                          82       43
  Hemoglobin \< 14.8 (g/dl)   0.59       32                         88                          85       37
  BNP ≥ 214 (pg/ml)           0.73       79                         56                          77       58
  LADs ≥ 45 (mm)              0.63       54                         67                          78       41
  EDV ≥ 166 (ml)              0.63       67                         58                          77       44
  ESV ≥ 89 (ml)               0.72       51                         85                          88       44
  LVEF \< 32 (%)              0.76       67                         72                          85       49
  **GLS ≥ -9.4 (%)**          **0.81**   **87**                     **86**                      **98**   **50**

Abbreviations: AUC--area under curve; BNP--brain natriuretic peptide; CI--confidence interval; HGB--hemoglobin; LADs--left atrium diameter; LVEF--left ventricular ejection fraction; EDV--left ventricular end-diastolic volume; ESV--left ventricular end-systolic volume; GFR--glomerular filtration rate; GLS--global longitudinal strain; QRS--QRS complex width

GLS maintained its statistical significance as a predictor of the EVENT even after adjusting to other above-mentioned parameters. [Fig 3](#pone.0225829.g003){ref-type="fig"} illustrates Kaplan-Meier's curve with the probability of the hospitalization due to HF exacerbation depending on pre-specified cut-off values for GLS during follow-up period.

![Kaplan-Meier curves illustrating probability of the hospitalization due to HF exacerbation after dichotomization according the pre-specified cut-off values for GLS during follow-up period.](pone.0225829.g003){#pone.0225829.g003}

Discussion {#sec015}
==========

In this study, we proved that GLS with a cut-off value of ≥ -9.4% is a statistically significant indicator of hospitalization due to HF decompensation, independent of other known risk factors in a well-defined group of stable individuals with ischemic cardiomyopathy with LVEF up to 50% who were optimally treated. In our opinion, assessment of GLS in clinical practice seems to be useful in identifying which patients should receive expanded ambulatory care to reduce the risk of HF exacerbations.

The role of GLS as a marker of cardiovascular events has been studied extensively in different groups of patients with regard to various endpoints \[[@pone.0225829.ref016], [@pone.0225829.ref027]--[@pone.0225829.ref030]\]. For example, in the study by Cho G et al., GLS was proved to be a predictor of the composite endpoint (cardiac mortality and HF exacerbations) in acute HF patients \[[@pone.0225829.ref027]\]. Nahum J et al., established the usefulness of GLS in the patients with chronic HF, but contrary to our study, they included patients with diverse HF etiology \[[@pone.0225829.ref028]\]. Buggey J et al., demonstrated the relationship between GLS and mortality or hospitalization for HF exacerbation in patients with acute HF and preserved EF (≥ 50%), however, this relationship was noted only in short-term observation \[[@pone.0225829.ref029]\].

GLS cut-off value of ≥ -9.4% determined in the present study in HF patients with LVEF up to 50% is within the range of values ​​presented by other authors, varying from about -7% to -14% \[[@pone.0225829.ref013], [@pone.0225829.ref031]--[@pone.0225829.ref034]\]. The value of this parameter is usually better in groups of patients with higher LVEF and worse in those with lower LVEF.

Particularly noteworthy is that GLS cut-off value established in the present study was characterized by the highest discriminatory power in revealing the risk of HF decompensation. AUC for GLS ≥ -9.4% was 0.81, while for broadly acknowledge LVEF it was lower (0.76). Furthermore, in the case of GLS values ​​≥ -9.4%, the relative risk of hospitalization due to HF decompensation was 15 times higher, while for others at most 2--3 fold. It is also worth to emphasize the very high PPV of GLS (98%), which was the highest PPV of all analyzed parameters. Sensitivity and specificity of this parameter were also high (87% and 86%, respectively). Thereby, GLS proved to be the strongest indicator of HF decompensation in the group of stable patients with ischemic cardiomyopathy with LVEF ≤ 50%. In addition, it is a quick and easy to obtain parameter, even at the patient\'s bedside, more objective and not based on geometrical assumptions, as in case of LVEF. GLS seems to be considered as a standard parameter evaluated in patients with HF for identification the most at-risk persons requiring special care.

Study limitations {#sec016}
=================

It was a small, single-center investigation and due to the relatively small number of patients, it was impossible to create a more stable subpopulation of patients who reached the endpoint, and thus the results need to be confirmed in a larger group of patients. Next, functional performance of the studied population was not evaluated \[[@pone.0225829.ref035]\] (for example by 6 minute walking test) and patients permanent atrial fibrillation were excluded from the study. Furthermore, other speckle tracking parameters, such as circumferential and radial strain, which are shown to be promising, were not evaluated \[[@pone.0225829.ref036]\]. Moreover, GLS was assessed using only one of the available vendor platforms, therefore the results may be slightly different from those received with alternative software algorithms \[[@pone.0225829.ref037]\].

Conclusions {#sec017}
===========

GLS derived by 2D STE can provide, independently of other well-known clinical parameters, information on the risk of hospitalization due to HF decompensation in the stable outpatients with LV systolic dysfunction of ischemic origin. Decreased GLS with cut-off value of ≥ -9.4% can identify the patients with the highest risk of such event, who require special care.
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